Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | XPO1 | O14980 | 13/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427778 | 1.00 | PIK3CD (0.46) | PIK3CDKDM4EALDH1A1KMT2AXPO1 | |
| SCHEMBL17826994 | 0.83 | KDM4E (0.39) | PIK3CDKDM4EALDH1A1KMT2AXPO1 | |
| Succinchlorimide SCHEMBL28310501 | 0.82 | XPO1 (0.43) | PIK3CDKDM4EALDH1A1KMT2AXPO1 | |
| SCHEMBL29388275 | 0.82 | XPO1 (0.46) | PIK3CDALDH1A1XPO1ADRB2RPS6KA5 | |
| SCHEMBL855349 | 0.82 | XPO1 (0.46) | PIK3CDALDH1A1XPO1ADRB2RPS6KA5 | |
| SCHEMBL11010121 | 0.76 | XPO1 (0.45) | PIK3CDXPO1ADRB2RPS6KA5 | |
| SCHEMBL30285418 | 0.76 | XPO1 (0.45) | PIK3CDXPO1ADRB2RPS6KA5 | |
| SCHEMBL11272404 | 0.76 | KDM4E (0.46) | PIK3CDKDM4EALDH1A1KMT2ABACE1 | |
| SCHEMBL24089023 | 0.74 | XPO1 (0.44) | PIK3CDXPO1ADRB2RPS6KA5 | |
| SCHEMBL7664844 | 0.74 | XPO1 (0.44) | KMT2AXPO1ADRB2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119462635-A | Quinoline derivatives as alpha 4 beta 7 integrin inhibitors | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118946555-A | Compounds having T-structures formed by at least four rings for use in the treatment of cancer and other indications | 瑟拉斯有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-112969687-B | Quinoline derivatives as a4 b 7 integrin inhibitors | 吉利德科学公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-112969700-B | Imidazopyridine derivatives as alpha 4 beta 7 integrin inhibitors | 吉利德科学公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-113015735-B | 5-Hydroxy-7-oxabicyclo [2.2.1] heptane-2-carboxamide derivatives for inducing chondrogenesis for the treatment of joint damage | 诺华股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118084870-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084867-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084866-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084868-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-4370515-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-112105419-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-112119075-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-116867792-A | Tetraepoxyazepine compound and use thereof | 基因泰克公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023287896-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |